Syner-Med Improves Sales Execution With Veeva OpenData

Veeva delivers the right data and insights for UK pharmaceutical
company
to drive tailored interactions with customers

PLEASANTON, Calif.–(BUSINESS WIRE)–#VeevaCRMVeeva
Systems
today announced that Syner-Med
(PP) Ltd.
, a fast-growing U.K. pharmaceutical company, is using Veeva
OpenData
and Veeva
CRM
to empower field teams with accurate customer data and drive
smarter engagement with customers. Veeva OpenData and Veeva CRM are part
of Veeva
Commercial Cloud
, a suite of applications that Syner-Med is adopting
to establish a foundation for their commercial operations as the company
launches more new products over the next two years.

“Veeva delivers quality customer data, right in CRM, to improve our
sales execution and create more valued interactions with our customers,”
said Dipak Bhatti, managing director of Syner-Med. “We now have the
foundation in place for a consistent commercial approach and to support
our future growth.”

Syner-Med’s previous data sources limited their ability to track
customer activities and placed a heavy administrative burden on field
reps to maintain accurate customer data. Data change requests could
often take weeks, so sales and marketing teams worked from outdated
information and had a fragmented view of customer engagement across the
company.

Veeva brings together complete customer data and multichannel engagement
to help Syner-Med achieve greater commercial effectiveness. Veeva
OpenData keeps data current using a combination of data science and
Veeva data stewards that can make change requests within two hours
versus the industry average of 10 days or more. As a result, field teams
have an accurate view of their customers in Veeva CRM to deliver
smarter, more informed interactions.

“Quality customer data is key to successful commercial execution and
increased sales and marketing efficiency,” said Rebecca Silver, global
vice president of Veeva OpenData. “With accurate data in Veeva CRM,
Syner-Med field and medical teams can drive more value-based
conversations with their customers.”

Veeva OpenData delivers access to approximately 16 million healthcare
professionals (HCPs) and their healthcare organizations (HCOs) spanning
42 countries. Veeva OpenData can help customers achieve greater
commercial success and improve sales execution and customer engagement.

Looking ahead, Syner-Med plans to adopt additional Veeva Commercial
Cloud applications, including Veeva
Vault PromoMats
to combine creation, review, and distribution of
commercial content with digital asset management; Veeva
Align
to perform fast, accurate territory alignments; Veeva
CRM Approved Email
and Veeva
CRM Engage
to extend reach through digital channels such as email,
online meetings, and virtual events; and Veeva
CLM
to tailor calls and make sales materials easy to access and
share.

Veeva Commercial Cloud is the life sciences industry’s trusted
foundation for intelligent customer engagement. To learn more about how
Veeva Commercial Cloud is helping life sciences companies place their
customers at the center of their commercial strategies, visit veeva.com/CommercialCloud.

Additional Information

For more on Veeva OpenData, visit: veeva.com/OpenData
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 600 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.

® 2017 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo
are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other
registered and unregistered trademarks.

Contacts

Veeva Systems
Roger Villareal, 925-264-8885
roger.villareal@veeva.com
or
Lisa
Barbadora, 610-420-3413
pr@veeva.com